retatrutide latest clinical trial results Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a Headline results published this week

Semaglutide (2.4mg, Wegovy): Approximately 14.9% body weight reduction over 68 weeks in the STEP trials

Third-party tested by independent ISO-certified laboratories

A vial that contains 70% purity retatrutide at a bargain price is not cheaper than a 98% purity vial at a premium price when you account for the dosing adjustments required, the inconsistent results, and the potential introduction of unknown impurities into your research

Individuals with a personal or family history of thyroid tumours should be aware that, in common with other GLP-1 receptor agonists, retatrutide's GLP-1 activity may carry a theoretical thyroid risk

But access may be expanding

Sold strictly for laboratory research use only